These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 8990355)

  • 21. The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients. The Neoral Study Group.
    Barone G; Bunke CM; Choc MG; Hricik DE; Jin JH; Klein JB; Marsh CL; Min DI; Pescovitz MD; Pollak R; Pruett TL; Stinson JB; Thompson JS; Vasquez E; Waid T; Wombolt DG; Wong RL
    Transplantation; 1996 Mar; 61(6):968-70. PubMed ID: 8623168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption.
    Trompeter R; Fitzpatrick M; Hutchinson C; Johnston A
    Pediatr Transplant; 2003 Aug; 7(4):282-8. PubMed ID: 12890006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
    Budde K; Bosmans JL; Sennesael J; Zeier M; Pisarski P; Schütz M; Fischer W; Neumayer HH; Glander P
    Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring.
    Sharma A; Shekhar C; Heer M; Minz M
    Transplant Proc; 2006 Sep; 38(7):2051-3. PubMed ID: 16979996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of generic cyclosporine arpimune in Filipino low-risk primary kidney transplant recipients.
    Pamugas GE; Danguilan RA; Lamban AB; Mangati VB; Ona ET
    Transplant Proc; 2012 Jan; 44(1):101-8. PubMed ID: 22310590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
    Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
    Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of the conventional and microemulsion formulations of cyclosporine in pancreas-kidney transplant recipients with gastroparesis.
    van der Pijl JW; Srivastava N; Denouël J; Burggraaf J; Schoemaker RC; van der Woude FJ; Cohen AF
    Transplantation; 1996 Aug; 62(4):456-62. PubMed ID: 8781610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
    Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
    Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of immediate switch from cyclosporine microemulsion to tacrolimus at first acute rejection in renal allograft recipients.
    Briggs D; Dudley C; Pattison J; Pfeffer P; Salmela K; Rowe P; Tydén G;
    Transplantation; 2003 Jun; 75(12):2058-63. PubMed ID: 12829912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open-label study of the safety and tolerability of converting stable liver transplant recipients to neoral.
    Pasha TM; Wiesner RH; Dahlke LM; Porayko MK; Krom RA
    Liver Transpl Surg; 1998 Sep; 4(5):410-5. PubMed ID: 9724479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
    White M; Pelletier GB; Tan A; Jesina C; Carrier M
    J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group.
    Barone G; Chang CT; Choc MG; Klein JB; Marsh CL; Meligeni JA; Min DI; Pescovitz MD; Pollak R; Pruett TL; Stinson JB; Thompson JS; Vasquez E; Waid T; Wombolt DG; Wong RL
    Transplantation; 1996 Mar; 61(6):875-80. PubMed ID: 8623152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral.
    Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
    Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function.
    Qazi YA; Forrest A; Tornatore K; Venuto RC
    Clin Transplant; 2006; 20(3):313-7. PubMed ID: 16824147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year.
    Neumayer HH; Budde K; Färber L; Haller P; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J; Luft FC
    Clin Nephrol; 1996 May; 45(5):326-31. PubMed ID: 8738665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation.
    Mahalati K; Belitsky P; Sketris I; West K; Panek R
    Transplantation; 1999 Jul; 68(1):55-62. PubMed ID: 10428267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic of cyclosporine microemulsion in pediatric kidney recipients receiving A quadruple immunosuppressive regimen: the value of C2 blood levels.
    Ferraresso M; Ghio L; Zacchello G; Murer L; Ginevri F; Perfumo F; Zanon GF; Fontana I; Amore A; Edefonti A; Vigano S; Cardillo M; Scalamogna M
    Transplantation; 2005 May; 79(9):1164-8. PubMed ID: 15880063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
    Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients.
    Kelles A; Herman J; Tjandra-Maga TB; Van Damme-Lombaerts R
    Pediatr Transplant; 1999 Nov; 3(4):282-7. PubMed ID: 10562972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.